Eczema Clinical Trial for ANB032

Testing a cutting-edge, injectable Eczema treatment for safety and effectiveness

A doctor is looking at research data on a tablet.

Welcome to our clinical research trial page for the study of ANB203 for Atopic Dermatitis (AD), or Eczema.

ANB203 is a new injectable biologic drug that has been chosen for research in its potential for turning off symptoms of Eczema in the body.

This novel form of treatment can be much more effective than topicals or creams for Eczema because it targets the underlying cause of symptoms.


  • 18-65 years of age.

  • At least 6 months of moderate or severe Eczema,
    affecting at least 10% of the skin’s surface.

  • A history of inadequate response to topical medications.

Volunteers will be paid for time and expenses.

The trial will last 7-8 months and require around 12 visits to the study centre.